GCG and type 2 diabetes mellitus: Currently, liraglutide in postmarketing GLP-1 RAs has been approved by the Food and Drug Administration (FDA) as a simple obesity drug due to its excellent weight loss effect and low risk of hypoglycemia in patients with type 2 diabetes mellitus (T2DM) [8].